We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,126.00
Bid: 12,126.00
Ask: 12,128.00
Change: -30.00 (-0.25%)
Spread: 2.00 (0.016%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Lower But Sirius Minerals And Greggs Gain

Mon, 11th Nov 2019 08:43

(Alliance News) - London stocks started the week on the back foot amid some rising unease over the US-China trade situation following a week of mixed headlines, with the FTSE 250 lower despite Sirius Minerals, Greggs and Aston Martin all racking up share price gains.

The FTSE 100 was 39.32 points lower, or 0.5%, at 7,320.06 early Monday. The FTSE 250 was down 65.24 points, or 0.3%, at 20,292.39, and the AIM All-Share was down 0.1% at 890.78.

The Cboe UK 100 index was up down 0.6% at 12,406.34. The Cboe UK 250 was down 0.1% at 18,233.01 and the Cboe UK Small Companies was flat at 11,258.26.

In European equities, the CAC 40 index in Paris was down 0.1% and the DAX 30 in Frankfurt down 0.3% in early trade.

In Asia on Monday, the Japanese Nikkei 225 index closed down 0.3%. In China, the Shanghai Composite ended down 1.8%, while the Hang Seng index in Hong Kong finished 2.6% lower.

"Civil unrest in Hong Kong and mixed signals on the progress of US/China trade talks has dampened sentiment across financial markets. Most Asian equity markets have started the week lower as a result, with Hong Kong stocks leading the decline following violent clashes this morning," said Lloyds Banking.

Though there were broad-based losses in the FTSE 100, AstraZeneca was sat atop the index, up 0.9% after reporting positive results for an anaemia drug.

Astra said analyses of a Roxadustat drug trial for the treatment of patients with anaemia from chronic kidney disease showed positive efficacy and no increased risk of major adverse cardiovascular events.

The FTSE 250 was lower despite some solid share price gains from the likes of Sirius Minerals, Greggs and Aston Martin.

Sirius Minerals shares surged 14% after outlining a new two-stage development plan for its North Yorkshire polyhalite mine as it looks to secure funding for the first stage of the project.

In September, Sirius announced it struggled to secure the required funding for its current project plan due to "market conditions." Consequently, the firm intended to slow the development of its polyhalite mine.

Sirius remains focused on extracting first polyhalite from the mine in order to remove the "greatest perceived construction risk associated with deep shaft construction." This will allow Sirius to explore a wider and cheaper range of long-term financing options for the ramping-up of production.

The Scarborough-based firm expects the initial phase to require around USD600 million in investment in addition to its current cash reserves.

Baker Greggs was up 6.9% after upgrading its guidance again.

In the period to November 9, total sales were up 12% year-on-year and the bakery chain registered like-for-like growth of 8.3% in its company-managed shops. In the same period last year, total sales rose by 8.3% and by 4.0% on a like-for-like basis.

The FTSE 250 firm now expects its full-year pretax profit, excluding exceptional costs, to be higher than previous internal expectations.

Greggs explained: "Sales growth continues to be driven by increased customer visits and has been stronger than we had expected given the improving comparative sales pattern that we saw in the fourth quarter last year. Operational costs remain well controlled and, whilst the comparative sales become stronger still in the balance of the year."

The company previously hiked its 2019 pretax profit guidance in February, after reporting a sales surge helped by its vegan sausage rolls.

Aston Martin shares rose 5.0% after HSBC raised the stock to Buy from Hold.

In Monday's economic calendar, there are UK GDP, manufacturing production, industrial production and trade balance reports at 0930 GMT.

"Given the weak PMIs, growth seems to remain sluggish but there might have been a positive contribution from stockpiling ahead of the previous 31 October Brexit deadline," commented Danske Bank.

Consensus, according to FXStreet, is for UK GDP in the third quarter of grow 0.3% quarter-on-quarter, after a 0.2% contraction in the preceding three months. Any reading which indicates the UK economy shrank in the three months to September will put the country into a technical recession.

The data comes after Moody's Investors Service on Friday downgraded the outlook for Britain's debt, citing mounting policy challenges amid the Brexit debate.

The agency cut the outlook to negative from stable but kept the debt at the investment-grade Aa2. Ratings agency Fitch had similarly put Britain on "negative watch" in February.

Pointing to "paralysis that has characterised the Brexit-era policymaking process," Moody's said London has "struggled to cope with the magnitude of policy challenges that they currently face."

The pound was quoted at USD1.2799 early Monday, up from USD1.2784 late Friday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.